AgomAb Therapeutics NV (NASDAQ:AGMB) Given Consensus Rating of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has been given an average rating of “Moderate Buy” by the five ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $32.75.

A number of equities analysts have weighed in on the company. Morgan Stanley assumed coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 target price on the stock. Leerink Partners assumed coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price objective on the stock. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Finally, HC Wainwright assumed coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $13.81 on Monday. The business has a 50-day simple moving average of $11.19. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.